KMTS General Counsel Traci S Umberger Sells $2.7M of Stock
Key Points
- General Counsel Traci S Umberger sold 100,000 shares of Kestra Medical Technologies, Ltd. for roughly $2.7 million on October 21, 2026, cutting her stake by about 33.8%.
- After the trade, Traci S Umberger holds 195,825 $KMTS shares, down 33.80% from before the trade.
- The planned sale took place as the stock traded recently around $28.32, sitting below its 52-week high of $30.00 and ahead of upcoming December earnings.
- Wall Street analysts hold a strong buy consensus on the medical device maker with a mean price target of $30.75.
Since the trade, $KMTS is up 3.7% to date (from the $27.31 close on Oct 21, 2026).
Get Kestra Medical Technologies, Ltd. text alerts
We text you when insiders, Congress, analysts or big funds move on $KMTS.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Kestra Medical Technologies, Ltd. alert may contain errors. Disclosures
Traci S Umberger, General Counsel and Chief Administrative Officer at Kestra Medical Technologies, Ltd. [KMTS], sold 100,000 shares of the company on October 21, 2026. The transaction was revealed in a Form 4 filing submitted to the Securities and Exchange Commission.
KMTS
Kestra Medical Technologies, Ltd.
Inside Traci S Umberger's Kestra Medical Trade
Umberger executed the sale at a price of $27.18 per share, bringing the total value of the transaction to roughly $2.7 million. The trade was carried out under a pre-arranged Rule 10b5-1 trading plan. Following the completion of the sale, Umberger retains direct ownership of 195,825 shares in the medical device company, marking a roughly 33.8% reduction in her personal shareholding.
Other Institutional Activity in Kestra Medical
Large financial firms have also adjusted their positions in the wearable cardiac monitoring company recently. Bain Capital Investors Llc held 25,172,338 shares worth about $712.9 million with no change to its share count. Andera Partners maintained a steady stake of 2,728,679 shares valued at about $77.3 million. Yu Fan held 2,282,519 shares worth roughly $64.6 million without adjusting holdings. Meanwhile, Brown Advisory Inc. grew its holdings by 185,303 shares, ending with 1,909,056 shares worth about $54.1 million following a 10.8% increase. Alliancebernstein L.P. lifted its stake by 157,649 shares, finishing with 1,477,992 shares valued at about $41.9 million after an 11.9% increase.
Kestra Medical Technologies, Ltd. Stock Up 3.7%
Shares recently traded around $28.32 as of October 22, 2026. That puts the stock roughly 5.6% below its 52-week high of $30.00 and well above its 52-week low of $17.34. The recent price sits about 7.1% above its 50-day moving average of $26.45 and about 19.8% above its 200-day moving average of $23.64.
Recent Earnings
Kestra Medical reported trailing twelve month revenue of $106.7 million alongside a net margin of -140.4% and a return on equity of -73.7%. The company's trailing twelve month earnings per share stood at -$2.67. The firm is scheduled to release its next financial results on December 14, 2026.
Insider Buying and Selling at Kestra Medical Technologies, Ltd.
Other company insiders have also parted with shares in recent months. Director Mary Kay Ladone sold 3,908 shares at an average price of $25.20 on September 8, 2026, for a total value of $98,464. On the same day, director and 10% owner Jeffrey Lawrence Schwartz sold 3,890 shares at $25.18 apiece, totaling $97,942. Director Elizabeth Kwo disposed of 4,010 shares at $24.26 on September 21, 2026, worth $97,268. Director Raymond W Cohen unloaded 3,330 shares at $29.28 on September 30, 2026, totaling $97,504.
Analysts Set New Price Targets
Wall Street coverage has evolved over recent months. Oppenheimer initiated coverage with a perform rating on July 21, 2026. JP Morgan initiated an overweight rating with a $30.00 price target on August 10, 2026. BTIG reiterated a buy rating with a $32.00 price target on September 2, 2026, and again on September 15, 2026. Evercore ISI Group initiated an outperform rating with a $34.00 price target on October 20, 2026. Overall, the company carries a strong buy recommendation from analysts, with a mean price target of $30.75 across eight analyst opinions.
About Kestra Medical Technologies, Ltd.
Kestra Medical Technologies designs wearable medical devices and digital healthcare tools aimed at improving patient outcomes in cardiovascular care. The firm focuses on connected monitoring systems, therapeutic devices, and data-driven clinical insights to help manage heart conditions. Insider transactions like this one provide a look at executive portfolio adjustments as the company continues developing its cardiac care products.
Bottom Line
Investors will look toward Kestra Medical's upcoming earnings report on December 14, 2026, for further updates on revenue growth and clinical developments. Form 4 filings will continue tracking whether other executives alter their personal equity positions.
Related Filing Alerts
Source: Traci S Umberger's Form 4 filing on $KMTS (Oct 21, 2026). Written by software, not financial advice. How we make alerts